{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:19:40Z","timestamp":1788185980538,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>C-X-C motif chemokine 9 (CXCL9), CXCL10, and CXCL11 are produced in response to interferon-\u03b3 (IFN-\u03b3) and trigger inflammation with the accumulation of activated lymphocytes. It appears that these chemokines could play a role in the pathogenesis of adult-onset Still\u2019s disease (AOSD). Therefore, we investigated the associations between the levels of these chemokine and clinical manifestations in patients with active AOSD. Serum levels of IFN-\u03b3, CXCL9, CXCL10 and CXCL11 were determined using enzyme-linked immunosorbent assays. IFN-\u03b3 levels were higher in AOSD patients than in rheumatoid arthritis (RA) patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) or healthy controls (HCs) (<jats:italic>p<\/jats:italic>\u2009=\u20090.032). AOSD patients also exhibited higher levels of CXCL9, CXCL10, and CXCL11 compared with RA patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and HCs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In follow-up AOSD patients after treatment with corticosteroid, the levels of CXCL9, CXCL10 and CXCL11 fell significantly, whereas IFN-\u03b3 levels were not significantly different. On immunohistochemistry, the percentage of CXCL10-positive inflammatory cells was higher in skin biopsy samples from AOSD patients than in those from normal control (<jats:italic>p<\/jats:italic>\u2009=\u20090.012), eczema (<jats:italic>p<\/jats:italic>\u2009=\u20090.019), and psoriasis (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) groups. Levels of the IFN-\u03b3\u2013induced chemokines, CXCL9, CXCL10 and CXCL11, were elevated and correlated with several disease activity markers. These interferon-\u03b3\u2013induced chemokines may contribute to inflammatory responses and skin manifestations in AOSD.<\/jats:p>","DOI":"10.1038\/srep46652","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T11:36:15Z","timestamp":1493033775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Elevated circulating levels of the interferon-\u03b3\u2013induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still\u2019s disease"],"prefix":"10.1038","volume":"7","author":[{"given":"Jae Ho","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yang","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Hwa","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunee","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"BFsrep46652_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","volume":"22","author":"B Fautrel","year":"2008","unstructured":"Fautrel, B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 22, 773\u2013792 (2008).","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"BFsrep46652_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters, E. G. Still\u2019s disease in the adult. Ann Rheum Dis 30, 121\u2013133 (1971).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep46652_CR3","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/ard.2005.046904","volume":"65","author":"JB Arlet","year":"2006","unstructured":"Arlet, J. B. et al. Reactive haemophagocytic syndrome in adult-onset Still\u2019s disease: a report of six patients and a review of the literature. Ann Rheum Dis 65, 1596\u20131601 (2006).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep46652_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot, J. et al. Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70, 118\u2013136 (1991).","journal-title":"Medicine (Baltimore)"},{"key":"BFsrep46652_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semarthrit.2006.07.001","volume":"36","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou, P. & Georgy, S. Pathogenesis and management of adult-onset Still\u2019s disease. Semin Arthritis Rheum 36, 144\u2013152 (2006).","journal-title":"Semin Arthritis Rheum"},{"key":"BFsrep46652_CR6","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi, J. H. et al. Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol 30, 2422\u20132427 (2003).","journal-title":"J Rheumatol"},{"key":"BFsrep46652_CR7","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen, D. Y., Lan, J. L., Lin, F. J. & Hsieh, T. Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol 31, 2189\u20132198 (2004).","journal-title":"J Rheumatol"},{"key":"BFsrep46652_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10067-012-1952-1","volume":"31","author":"T Kasama","year":"2012","unstructured":"Kasama, T. et al. Correlation of serum CX3CL1 level with disease activity in adult-onset Still\u2019s disease and significant involvement in hemophagocytic syndrome. Clin Rheumatol 31, 853\u2013860 (2012).","journal-title":"Clin Rheumatol"},{"key":"BFsrep46652_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13075-015-0773-4","volume":"17","author":"JH Han","year":"2015","unstructured":"Han, J. H. et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still\u2019s disease. Arthritis Res Ther 17, 260 (2015).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep46652_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89, 207\u2013215 (2011).","journal-title":"Immunol Cell Biol"},{"key":"BFsrep46652_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","volume":"26","author":"K Van Raemdonck","year":"2015","unstructured":"Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J. & Struyf, S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev 26, 311\u2013327 (2015).","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFsrep46652_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/labinvest.3700453","volume":"86","author":"T Loos","year":"2006","unstructured":"Loos, T. et al. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest 86, 902\u2013916 (2006).","journal-title":"Lab Invest"},{"key":"BFsrep46652_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1189\/jlb.1003524","volume":"75","author":"P Proost","year":"2004","unstructured":"Proost, P. et al. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J Leukoc Biol 75, 777\u2013784 (2004).","journal-title":"J Leukoc Biol"},{"key":"BFsrep46652_CR14","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/eji.200324136","volume":"33","author":"P Proost","year":"2003","unstructured":"Proost, P. et al. Microbial Toll-like receptor ligands differentially regulate CXCL10\/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 33, 3146\u20133153 (2003).","journal-title":"Eur J Immunol"},{"key":"BFsrep46652_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13, 272\u2013280 (2014).","journal-title":"Autoimmun Rev"},{"key":"BFsrep46652_CR16","doi-asserted-by":"publisher","first-page":"R241","DOI":"10.1186\/ar783","volume":"5","author":"P Ruschpler","year":"2003","unstructured":"Ruschpler, P. et al. High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis. Arthritis Res Ther 5, R241\u2013252 (2003).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep46652_CR17","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar1913","volume":"8","author":"DS Pharoah","year":"2006","unstructured":"Pharoah, D. S. et al. Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells. Arthritis Res Ther 8, R50 (2006).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep46652_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MD.0b013e3181caf100","volume":"89","author":"A Hot","year":"2010","unstructured":"Hot, A. et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore) 89, 37\u201346 (2010).","journal-title":"Medicine (Baltimore)"},{"key":"BFsrep46652_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/ph8040793","volume":"8","author":"A Avau","year":"2015","unstructured":"Avau, A & Matthys, P. Therapeutic Potential of Interferon-gamma and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Pharmaceuticals (Basel) 8, 793\u2013815 (2015).","journal-title":"Pharmaceuticals (Basel)"},{"key":"BFsrep46652_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1172\/JCI31860","volume":"117","author":"J Zhang","year":"2007","unstructured":"Zhang, J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 117, 871\u2013873 (2007).","journal-title":"J Clin Invest"},{"key":"BFsrep46652_CR21","first-page":"396","volume":"25","author":"T Hoshino","year":"1998","unstructured":"Hoshino, T. et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still\u2019s disease. J Rheumatol 25, 396\u2013398 (1998).","journal-title":"J Rheumatol"},{"key":"BFsrep46652_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/art.21164","volume":"53","author":"DY Chen","year":"2005","unstructured":"Chen, D. Y., Lan, J. L., Lin, F. J. & Hsieh, T. Y. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still\u2019s disease. Arthritis Rheum 53, 320\u2013327 (2005).","journal-title":"Arthritis Rheum"},{"key":"BFsrep46652_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.smim.2013.10.014","volume":"25","author":"D Novick","year":"2013","unstructured":"Novick, D., Kim, S., Kaplanski, G. & Dinarello, C. A. Interleukin-18, more than a Th1 cytokine. Semin Immunol 25, 439\u2013448 (2013).","journal-title":"Semin Immunol"},{"key":"BFsrep46652_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","volume":"44","author":"M Kawashima","year":"2001","unstructured":"Kawashima, M. et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease. Arthritis Rheum 44, 550\u2013560 (2001).","journal-title":"Arthritis Rheum"},{"key":"BFsrep46652_CR25","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/art.20268","volume":"50","author":"N Maeno","year":"2004","unstructured":"Maeno, N. et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 50, 1935\u20131938 (2004).","journal-title":"Arthritis Rheum"},{"key":"BFsrep46652_CR26","doi-asserted-by":"crossref","unstructured":"Bracaglia, C. et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis (2016).","DOI":"10.1136\/annrheumdis-2015-209020"},{"key":"BFsrep46652_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","volume":"194","author":"J Flier","year":"2001","unstructured":"Flier, J. et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194, 398\u2013405 (2001).","journal-title":"J Pathol"},{"key":"BFsrep46652_CR28","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1172\/JCI71951","volume":"124","author":"Y Zohar","year":"2014","unstructured":"Zohar, Y. et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 124, 2009\u20132022 (2014).","journal-title":"J Clin Invest"},{"key":"BFsrep46652_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1084\/jem.184.3.963","volume":"184","author":"M Loetscher","year":"1996","unstructured":"Loetscher, M. et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184, 963\u2013969 (1996).","journal-title":"J Exp Med"},{"key":"BFsrep46652_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1046\/j.1523-1747.1999.00730.x","volume":"113","author":"J Flier","year":"1999","unstructured":"Flier, J. et al. The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 113, 574\u2013578 (1999).","journal-title":"J Invest Dermatol"},{"key":"BFsrep46652_CR31","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","volume":"54","author":"KS van der Geest","year":"2015","unstructured":"van der Geest, K. S. et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford) 54, 1397\u20131402 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep46652_CR32","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi, M. et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol 19, 424\u2013430 (1992).","journal-title":"J Rheumatol"},{"key":"BFsrep46652_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum"},{"key":"BFsrep46652_CR34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271\u20131277 (1982).","journal-title":"Arthritis Rheum"},{"key":"BFsrep46652_CR35","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1097\/MD.0000000000000787","volume":"94","author":"HA Kim","year":"2015","unstructured":"Kim, H. A. et al. The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94, e787 (2015).","journal-title":"Medicine (Baltimore)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep46652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep46652","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep46652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep46652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:39:01Z","timestamp":1671817141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep46652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,11]]}},"alternative-id":["BFsrep46652"],"URL":"https:\/\/doi.org\/10.1038\/srep46652","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]},"assertion":[{"value":"12 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46652"}}